Increased Levels of Müllerian Inhibiting Substance Could Mean Greater Breast Cancer Risk
PHILADELPHIA (October 9, 2009) – Women with increased levels of Müllerian inhibiting substance (MIS), best known for regulating in utero sexual differentiation in boys, may be at a greater risk for breast cancer, according to a new study published online today in the Journal of the National Cancer Institute.
To determine whether MIS levels were associated with breast cancer risk, Joanne F. Dorgan, PhD, MPH, of the Fox Chase Cancer Center in Philadelphia, and colleagues conducted a prospective case-control study of 309 participants who were registered in the Columbia, Missouri Serum Bank. Blood samples were donated by women with in situ or invasive breast cancer who, at the time of donation, were free of cancer. Each of 105 breast cancer patients was matched to two control subjects. MIS was measured in serum using an enzyme-linked immunosorbent assay.
Researchers found that increasing MIS serum concentrations were associated with increased breast cancer risk in this population.
“Additional research is needed, including confirmatory epidemiological studies on the association of serum MIS with breast cancer and studies aimed at identifying the biological mechanism underlying the association,” the authors write.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.